CLDX · Celldex Therapeutics, Inc.
AI read · Neutral
The AI's read
The 8-K attaches a press release saying Celldex announced results from two Phase 3 EMBARQ-CSU trials of barzolvolimab. The filing text does not include the actual trial outcomes, so it provides no new basis to change Celldex's outlook.